For properly selected patients, laparoscopically assisted total gastrectomy can be a curative and minimally invasive treatment for early gastric cancer.

These results suggest that determining the plasma level of VEGF-C would be useful for predicting lymphatic invasion, venous invasion and poor outcome of patients with colorectal cancer.

The DEILO procedure appears to shorten the operating time for ESD, with comparable efficacy and complication rates.

We investigtated the preventive and inhibitory effects of goshajinkigan with regard to oxaliplatin-induced peripheral neuropathy in 29 patients who received mFOLFOX6 (± bevacizumab) for colorectal cancer in the Department of Surgery at Gunma Saiseikai Maebashi Hospital, from January to December 2010. A comparison was made between 3 groups: prophylactic coadministration of goshajinkigan group (combined with mFOLFOX6 at beginning (± bevacizumab)), therapeutic coadministration of goshajinkigan group (combined with mFOLFOX6 at onset of peripheral neuropathy (≦ grade1)) group and no goshajinkigan group. The endpoints were grade changes in peripheral neuropathy associated with continuous mFOLFOX6 (± bevacizumab), inhibitory effect ≧ grade1 and ≧ grade2 neurotoxicity in relation to the total dose of oxaliplatin, and TTF of mFOLFOX6 (± bevacizumab). The inhibitory effect with respect to peripheral neuropathy and TTF were investigated using Kaplan-Meier analysis and tested by the Log-Rank test. The results for all endpoints suggested that goshajinkigan had preventive and inhibitory effects in oxaliplatin-induced peripheral neuropathy where prophylactic coadministration of goshajinkigan ＞therapeutic coadministration of goshajinkigan＞ no goshajinkigan. Prophylactic coadministration of goshajinkigan achieved a significant inhibitory effect in grade 2 or worse peripheral neuropathy in relation to the total dose of oxaliplatin (p = 0.002). These findings suggest that goshajinkigan can be used as a prophylactic and therapeutic agent in oxaliplatin-induced peripheral neuropathy.